Added to YB: 2025-11-14
Pitch date: 2025-11-09
MEDCL.PA [bullish]
MedinCell S.A.
-23.91%
current return
Author Info
No bio for this author
Company Info
MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France.
Market Cap
EUR 879.8M
Pitch Price
EUR 31.70
Price Target
N/A
Dividend
N/A
EV/EBITDA
-44.97
P/E
-26.06
EV/Sales
35.71
Sector
Pharmaceuticals
Category
growth
MedinCell's 'Shift to Growth' strategy validated; blockbuster drug Olanzapine expected in 2026
MEDCL.PA: UZEDY sales hit $136M (+82% YOY), targeting $190-200M 2025 with 5-9% royalties to MedinCell. Olanzapine LAI 'blockbuster' potential $1.5-2.9B market, FDA filing Q4 2025, approval/launch end 2026. AbbVie partnership worth $315M+ milestones. Operational profitability targeted 2026-27.
Read full article (3 min)